Mossler Mark 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CAO Mark Mossler Receives RSU Award, Vests Shares
What Happened
- Mark Mossler, Chief Accounting Officer of C4 Therapeutics (CCCC), received a grant of 56,980 restricted stock units (RSUs) on Feb 13, 2026. On Feb 14, 2026, 9,420 shares were acquired upon vesting/conversion of previously disclosed RSUs. To satisfy withholding tax obligations, 3,268 shares were withheld by the issuer at a reported price of $1.89 per share (withholding value ≈ $6,177).
- These actions are award/vesting events (not an open-market purchase or directional sale), and the 3,268-share withholding is a routine tax withholding (not a sale by Mossler, per the filing footnote).
Key Details
- Transaction dates: Grant 2026-02-13 (56,980 RSUs); Vesting/conversion 2026-02-14 (9,420 shares); Tax withholding 2026-02-14 (3,268 shares at $1.89, ≈ $6,177).
- Prices/values reported: RSUs granted at $0.00 (typical for equity awards); withheld shares valued at $1.89 each for tax withholding.
- Shares owned after transaction: Not specified in the excerpt provided.
- Footnotes of note:
- F1: RSU vesting schedule — 28,490 RSUs vest in three equal annual installments (first installment Feb 13, 2027); the other 28,490 RSUs vest in full on Feb 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- F2: The 9,420 shares reflect vesting/settlement of previously reported RSU grants (originally disclosed 4/10/2024 and 2/18/2025).
- F3: The 3,268-share disposition represents issuer withholding to satisfy tax obligations and is not a sale by the reporting person.
- Filing timeliness: Form filed Feb 18, 2026 covering Feb 13–14 transactions; the filing excerpt provided does not indicate a late-filing flag.
Context
- Equity awards and RSU vesting are common compensation events for executives and are generally routine; the grant increases potential future ownership if vesting conditions are met. The conversion on Feb 14 appears to be settlement of earlier RSUs rather than an option exercise for cash proceeds. Tax-withholding via share retention is a standard administrative step and does not necessarily signal insider sentiment.
Insider Transaction Report
Form 4
Mossler Mark
Chief Accounting Officer
Transactions
- Award
Common Stock
[F1]2026-02-13+56,980→ 75,184 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+9,420→ 75,184 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−3,268$6,177→ 71,916 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 28,490 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 28,490 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on April 10, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Signature
/s/ Shagha Russell, Attorney-in-Fact|2026-02-18